6 days ago
1
koto_feja/E+ via Getty Images
- Instil Bio (NASDAQ:TIL) said on Wednesday that the FDA has cleared the company's antibody therapy, AXN-2510, for trials as a treatment for solid tumors.
- Instil plans to commence a phase 1 trial of ‘2510 as a standalone treatment for patients with
English (US) ·